Breast Cancer Medicines Available in the Philippines — 2026 Guide

Breast cancer is the most commonly diagnosed cancer among Filipino women, accounting for approximately 20% of all female cancers in the Philippines. While a diagnosis is frightening, breast cancer treatment has advanced dramatically in recent years — the right medicine, matched to the right breast cancer subtype, can achieve remission and allow patients to live full, active lives.

This guide explains the main types of breast cancer, the medicines used to treat each, and how Filipino patients can access them — including affordable generic options through Pinoymeds.

Understanding Breast Cancer Subtypes

Not all breast cancers are the same. The three key biomarker tests your oncologist will order determine your breast cancer subtype and drive treatment decisions:

The major subtypes:
– HR+/HER2- (Hormone Receptor Positive, HER2 Negative) — most common (~70% of cases)
– HER2+ (any HR status) — ~15–20% of cases
– Triple-Negative Breast Cancer (TNBC) — no ER, PR, or HER2 expression; ~15% of cases

Medicines for HR+/HER2- Breast Cancer

Endocrine (Hormone) Therapy

Since HR+ breast cancer is driven by estrogen or progesterone, removing or blocking these hormones is foundational. Medicines include:

• Tamoxifen — standard for pre-menopausal women; oral tablet; available in Philippines pharmacies
• Aromatase inhibitors (Letrozole, Anastrozole, Exemestane) — for post-menopausal women; widely available in Philippines pharmacies at low cost
• Fulvestrant (Faslodex) — injectable; blocks estrogen receptor; used in advanced or treatment-resistant cases

These are generally affordable and widely available. The key challenge comes when advanced HR+ disease needs escalation to targeted combination therapy.

CDK4/6 Inhibitors (The Game-Changers)

The most significant advance in HR+/HER2- advanced breast cancer in the last decade has been CDK4/6 inhibitors — a class of targeted medicines that block proteins (CDK4 and CDK6) that cancer cells need to divide.

Combined with endocrine therapy, CDK4/6 inhibitors have nearly doubled progression-free survival in advanced HR+/HER2- breast cancer compared to endocrine therapy alone.

Available CDK4/6 inhibitors:

Pricing (indicative):
– Branded Ibrance (Palbociclib): ₱200,000–₱300,000/month
– Generic Palbociclib via Pinoymeds: ₱18,000–₱35,000/month

The generic price difference makes long-term CDK4/6 inhibitor treatment actually sustainable for Filipino patients.

PI3K/mTOR Pathway Inhibitors

For HR+ disease that has progressed on CDK4/6 inhibitors:
– Everolimus (Afinitor) combined with Exemestane — mTOR inhibitor
– Alpelisib (Piqray) — for PIK3CA-mutated HR+ advanced breast cancer; requires PIK3CA mutation testing

These are typically second or third-line options and can be sourced through Pinoymeds.

Medicines for HER2-Positive Breast Cancer

HER2+ breast cancer grows rapidly but responds exceptionally well to anti-HER2 targeted therapies. Treatment has transformed from a subtype with poor prognosis to one with excellent outcomes when treated correctly.

Anti-HER2 Targeted Therapies

Key challenge: Trastuzumab and Pertuzumab are IV-infused medicines given at hospital infusion centres — they cannot be home-delivered and must be administered under medical supervision. Costs are very high for branded versions.

Biosimilar Trastuzumab — biosimilar versions of Trastuzumab (Herceptin) have been approved by international regulatory bodies and are available at significantly lower cost. Pinoymeds can advise on biosimilar options.

For oral anti-HER2 medicines (Lapatinib, Neratinib, Tucatinib), home delivery is possible through the standard Pinoymeds import process.

Medicines for Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer (no ER, PR, or HER2 expression) is the most challenging subtype to treat because it doesn’t respond to hormone therapy or anti-HER2 therapy. Treatment options include:

Chemotherapy

Standard platinum-based regimens (Carboplatin, Paclitaxel) remain the backbone of TNBC treatment. These are administered at hospital infusion centres.

Immunotherapy

• Pembrolizumab (Keytruda) combined with chemotherapy — for PD-L1-positive TNBC. A major advance in early-stage and metastatic TNBC.
• Pembrolizumab is available through specialist import pathways — contact Pinoymeds.

PARP Inhibitors (for BRCA-mutated TNBC)

• Olaparib (Lynparza) and Talazoparib (Talzenna) — for patients with inherited BRCA1/2 mutations
• Requires BRCA genetic testing
• Available through Pinoymeds import pathway

Antibody-Drug Conjugates

• Sacituzumab Govitecan (Trodelvy) — a newer ADC showing strong results in metastatic TNBC
• Contact Pinoymeds for access pathway

Getting BRCA and HER2 Testing in the Philippines

Before receiving many advanced breast cancer therapies, you’ll need molecular testing:

• HER2 testing (IHC + FISH): Standard, available at most oncology centres
• BRCA1/2 germline testing: Available at select laboratories; cost ₱15,000–₱35,000; increasingly covered by PhilHealth for eligible patients
• PIK3CA mutation testing: For consideration of Alpelisib in HR+ disease; available at select molecular pathology labs

Ask your oncologist which tests you need before your treatment planning meeting.

How to Access Breast Cancer Medicines in the Philippines

Step 1: Confirm Your Breast Cancer Subtype

Ensure your pathology report includes ER, PR, HER2 status, and Ki-67. This drives every treatment decision.

Step 2: Get a Treatment Plan from Your Oncologist

Your oncologist will propose a regimen based on your subtype, stage, and fitness. If your prescribed medicines are not available locally, ask for a prescription to initiate import.

Step 3: Contact Pinoymeds

Share your prescription with our team. We will:
– Confirm availability and pricing (branded and generic)
– Begin the FDA import permit process
– Advise on combining PCSO/PhilHealth assistance

Step 4: Apply for Financial Assistance in Parallel

• Submit PCSO medical assistance application using Pinoymeds quotation
• Claim PhilHealth Z Benefit if you have eligible breast cancer coverage
• Check Malasakit Center at your hospital for combined government support

Frequently Asked Questions

Q: Is Ibrance (Palbociclib) available in the Philippines?
A: Branded Ibrance is available through licensed importers and some hospitals. Generic Palbociclib is available through Pinoymeds at significantly lower cost — typically ₱18,000–₱35,000/month vs ₱200,000+ for branded.

Q: Do I need HER2 testing before buying anti-HER2 medicines?
A: Yes. Anti-HER2 therapies like Trastuzumab are only indicated for HER2-positive patients. Testing is required for proper treatment and is a prerequisite for prescriptions.

Q: My breast cancer has spread to my bones. What medicines help?
A: Bone metastases in HR+ disease are often managed with endocrine therapy + CDK4/6 inhibitor + bone-protecting agents (Bisphosphonates: Zoledronic acid; or Denosumab). Your oncologist will specify the regimen.

Q: Can I get CDK4/6 inhibitors through PCSO?
A: PCSO medical assistance is medicine-agnostic — it provides financial assistance regardless of which medicine is prescribed. You can use Pinoymeds quotation documents to support your PCSO application.

Q: Is there a generic version of Herceptin (Trastuzumab)?
A: Yes — biosimilar Trastuzumab (biologically equivalent to Herceptin) is available. Contact Pinoymeds for current sourcing options for your specific regimen.

Q: I was diagnosed with early-stage HER2+ breast cancer. Do I still need targeted therapy?
A: Yes. For HER2+ early-stage breast cancer, Trastuzumab-based adjuvant treatment significantly reduces the risk of recurrence. Your oncologist will recommend the appropriate regimen.

Pinoymeds: Your Partner in Breast Cancer Treatment

Whether you’re navigating HR+ advanced breast cancer, facing the costs of Ibrance or Herceptin, or looking for a second opinion from a Filipino oncologist, Pinoymeds is here to help.

• 408+ specialty medicines including all major breast cancer treatments
• Generic options for oral breast cancer medicines — up to 91% cheaper than branded
• Free doctor consultation with Filipino oncologists
• Nationwide delivery across the Philippines
• Expert support in PCSO and PhilHealth assistance navigation

Contact us today — WhatsApp, Viber, or Telegram.

This article is for informational purposes only. All treatment decisions must be made with your licensed oncologist based on your specific diagnosis and pathology.

Related: View all blog medications